congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Quizartinib
ASH 2023 | December 9-12, 2023
CHIP-AML22 master protocol: An open-label clinical trial in newly diagnosed pediatric de novo acute myeloid leukemia patients including a linked phase II trial with quizartinib in FLT3-ITD/NPM1WT patients – a study by the NOPHO-DB-SHIP consortium
Oral
Valemetostat
ASH 2023 | December 9-12, 2023
Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 studya
Poster
Quizartinib
ASH 2023 | December 9-12, 2023
Kinetics of complete remission and complete remission duration and its impact on overall survival and event-free survival in QuANTUM-First
Oral
Quizartinib
ASH 2023 | December 9-12, 2023
Patient-reported outcomes in acute myeloid leukemia patients with FLT3-ITD mutation receiving quizartinib vs. standard chemotherapy: Results from the QuANTUM-First trial
Oral
Quizartinib
ASH 2023 | December 9-12, 2023
QuANTUM-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients
Poster
Quizartinib
ASH 2023 | December 9-12, 2023
QuANTUM-First: Clinical bridging study for FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) companion diagnostic development
Oral
Quizartinib
ASH 2023 | December 9-12, 2023
QuANTUM-First: Safety by treatment phase and by age in newly diagnosed patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia
Poster
Valemetostat
ASH 2023 | December 9-12, 2023
Valemetostat for relapsed or refractory B-cell lymphomas: Primary results from a phase 1 trial
Oral
Valemetostat
ASH 2023 | December 9-12, 2023
Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial